Natixis Lowers Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Natixis decreased its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) by 40.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,789 shares of the biotechnology company’s stock after selling 48,906 shares during the period. Natixis’ holdings in Cerevel Therapeutics were worth $3,035,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Headlands Technologies LLC purchased a new stake in shares of Cerevel Therapeutics in the first quarter valued at approximately $26,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $71,000. Centaurus Financial Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $119,000. GAM Holding AG purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at approximately $212,000. Finally, Virtu Financial LLC purchased a new stake in Cerevel Therapeutics during the fourth quarter worth $246,000. Hedge funds and other institutional investors own 87.73% of the company’s stock.

Insiders Place Their Bets

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the sale, the director now owns 25,928 shares in the company, valued at $1,067,715.04. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 5.10% of the stock is owned by company insiders.

Cerevel Therapeutics Price Performance

Cerevel Therapeutics stock traded up $0.06 during mid-day trading on Friday, reaching $44.46. 84,135 shares of the company were exchanged, compared to its average volume of 1,587,928. The business has a fifty day moving average of $41.34 and a 200 day moving average of $41.82. The company has a quick ratio of 10.22, a current ratio of 10.22 and a debt-to-equity ratio of 0.60. Cerevel Therapeutics Holdings, Inc. has a 12-month low of $19.59 and a 12-month high of $44.54.

Cerevel Therapeutics (NASDAQ:CERE) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.12). As a group, research analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 EPS for the current fiscal year.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.